Research interests include: drug-induced liver injury, biomarkers, liver regeneration, and clinical laboratory testing.
Mark Manzano, Ph.D.
We are interested in studying primary effusion lymphoma (PEL), an aggressive B cell cancer caused by the Kaposi’s sarcoma-associated herpesvirus or human herpesvirus 8 (KSHV/HHV8). PEL tumor cells rely on the constitutive expression of virally encoded genes that globally reprogram host gene expression to create a conducive environment optimal for tumor cell proliferation and survival.
Yuet-Kin “Ricky” Leung, Ph.D.
Dr. Leung is an established investigator in the field of hormone regulation of cancer and is an expert on the developmental origin of cancer risk and the impact of environmental estrogens/endocrine disruption on epigenetics reprogramming.
Shuk-Mei Ho, Ph.D.
Dr. Ho’s research interests pertain to the role of hormones and endocrine disruptors, and the interplay between genetics and epigenetics, in disease development as well as how early-life experiences can be a root cause in later development of cancers, asthma, neural disorders and other complex chronic diseases.
Lisa K. Brents, Ph.D.
The objective of my laboratory is to develop treatment strategies for opioid use disorder that can be administered to pregnant women without negatively affecting fetuses.
John M. Arthur, M.D., Ph.D.
I am a physician-scientist with research and clinical interests in the prediction of outcomes in kidney disease. The research in my laboratory focuses on the discovery and validation of biomarkers in renal diseases including acute kidney injury, diabetic nephropathy, chronic kidney disease and glomerular diseases like IgA nephropathy. We use targeted analysis of candidate markers […]
Wei Li
Lisa Jansen
Samrat Roy Choudhury, Ph.D., MSc
Dr. Roy Choudhury’s research focuses on investigating the epigenetic regulatory mechanisms at the enhancers and promoters of the critical oncogenes and tumor suppressors that drive malignant proliferation and invasion during leukemogenesis in the Acute Myeloid Leukemia (AML) patients, characterized with BET (BRD4), SET (KMT2A, EZH2, and NSD1) or runt (CBFA2T3) over-expressed domains. His laboratory uses […]